Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Squamous cell lung cancer: gene targets

Paul Paik • 3 Jun 2019
ASCO 2019
Lung Cancer

Here, Paul Paik of the Memorial Sloan Kettering Cancer Center, New York, NY discusses the development of treatments for squamous cell lung cancer and the importance of identifying new targets such as NFA202. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Paul Paik

2:48
VISION trial: subset efficacy analyses of tepotinib for NSCLC
Paul Paik • 26 Jan 2021
2:49
The challenges of treating METex14 NSCLC
Paul Paik • 26 Jan 2021
0:53
Future treatment options for squamous cell lung cancer
Paul Paik • 3 Jun 2019
1:04
Tepotinib: advanced non-small cell lung cancer
Paul Paik • 4 Jul 2019

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals